Difference between revisions of "ENST00000412654.1"
Chunlei Yu (talk | contribs) (→Transcriptomic Nomeclature) |
|||
| Line 3: | Line 3: | ||
==Annotated Information== | ==Annotated Information== | ||
===Name=== | ===Name=== | ||
| − | PCA3:prostate cancer associated 3 (non-protein coding) | + | PCA3:prostate cancer associated 3 (non-protein coding) [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8637 (HGNC:8637)] |
| + | ===Aliases=== | ||
| + | "non-protein coding RNA 19"; ''PCAT3'': "prostate cancer associated transcript 3 (non-protein coding)"<ref name="ref1" /> | ||
| − | + | ''DD3'', NCRNA00019 <ref name="ref2" /> | |
| − | |||
| − | ''DD3'', NCRNA00019<ref name="ref2" /> | ||
===Charateristics=== | ===Charateristics=== | ||
| Line 15: | Line 15: | ||
PCA3 whose expression at different PCa stages is involved in PCa survival pathways by controlling cell growth and viability, at least in part through controlling the AR pro-survival signaling<ref name="ref1" />. | PCA3 whose expression at different PCa stages is involved in PCa survival pathways by controlling cell growth and viability, at least in part through controlling the AR pro-survival signaling<ref name="ref1" />. | ||
| − | |||
| − | |||
===Expression=== | ===Expression=== | ||
PCA3 is expressed in higher levels in the androgen-responsive cell line (LNCaP)<ref name="ref1" />. | PCA3 is expressed in higher levels in the androgen-responsive cell line (LNCaP)<ref name="ref1" />. | ||
| Line 59: | Line 57: | ||
| | TCCTGCCCATCCTTTAAGG<ref name="ref1" /> | | | TCCTGCCCATCCTTTAAGG<ref name="ref1" /> | ||
|} | |} | ||
| + | |||
| + | ===Disease=== | ||
| + | * prostate-cancer<ref name="ref1" /> | ||
==Labs working on this lncRNA== | ==Labs working on this lncRNA== | ||
| − | Instituto Nacional do Câncer/Programa de Carcinogênese Molecular and Programa de Pós Graduação Stricto Sensu em Oncologia, Rio de Janeiro, Brazil<ref name="ref1" />. | + | * Instituto Nacional do Câncer/Programa de Carcinogênese Molecular and Programa de Pós Graduação Stricto Sensu em Oncologia, Rio de Janeiro, Brazil<ref name="ref1" />. |
| − | + | * Urology Research Laboratory, University Hospital Nijmegen, The Netherlands<ref name="ref2" />. | |
| − | Urology Research Laboratory, University Hospital Nijmegen, The Netherlands<ref name="ref2" />. | ||
==References== | ==References== | ||
<references> | <references> | ||
| − | <ref name="ref1">Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling[J]. BMC cancer. 2012,12:507.</ref>(1) | + | <ref name="ref1"> Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling[J]. BMC cancer. 2012,12:507.</ref>(1) |
| − | <ref name="ref2">Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer research. 1999,59(23):5975-9.</ref>(2) | + | <ref name="ref2"> Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer research. 1999,59(23):5975-9.</ref>(2) |
</references> | </references> | ||
Latest revision as of 09:34, 21 November 2018
PCA3 is one of the most prostate-specific genes described to date, is highly overexpressed in PCa tumors, and has been extensively characterized as a tumor biomarker。
Contents
Annotated Information
Name
PCA3:prostate cancer associated 3 (non-protein coding) (HGNC:8637)
Aliases
"non-protein coding RNA 19"; PCAT3: "prostate cancer associated transcript 3 (non-protein coding)"[1]
DD3, NCRNA00019 [2]
Charateristics
The noncoding RNA PCA3, which was initially characterized as Differential Display Code 3 (DD3), is prostate-tissue-specific and highly overexpressed in more than 95% of primary prostate cancers. PCA3 transcript has splicing and alternative polyadenylation, and a very short open reading frame[1].
Function
PCA3 whose expression at different PCa stages is involved in PCa survival pathways by controlling cell growth and viability, at least in part through controlling the AR pro-survival signaling[1].
Expression
PCA3 is expressed in higher levels in the androgen-responsive cell line (LNCaP)[1].
Oligonucleotide primers used for analysis of RT-PCR and qRT-PCR expression of androgen receptor-responsive genes and PCA3 transcript are as follows,
| Gene | Primer Forward 5'-3' | Primer Reverse 5'-3' |
|---|---|---|
| PMEPA1 | CATGATCCCCGAGCTGCT | TGATCTGAACAAACTCCAGCTCC[1] |
| 18S | AACCCGTTGAACCCCATT | CGCTACTACCGATTGGATGG[1] |
| GAPDH | TGACCCCTTCATTGACCTCA | AGTCCTTCCACGATACCAAA[1] |
| TMPRSS2 | CTGGTGGCTGATAGGGGATA | GGACAAGGGGTTAGGGAGAG[1] |
| NDRG1 | CGAGACTTTACATGGCTCTG | GCATTGATGAACAGGTGCAG[1] |
| GREB1 | AAGGAGGGCTGGAAACAAAT | CATTGTGGCCATTGTCATCT[1] |
| PCA3 : 69-F | AGATTTGTGTGGCTGCAGC[1] | |
| PCA3 : 510-R | TCCTGCCCATCCTTTAAGG[1] |
Disease
- prostate-cancer[1]
Labs working on this lncRNA
- Instituto Nacional do Câncer/Programa de Carcinogênese Molecular and Programa de Pós Graduação Stricto Sensu em Oncologia, Rio de Janeiro, Brazil[1].
- Urology Research Laboratory, University Hospital Nijmegen, The Netherlands[2].
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling[J]. BMC cancer. 2012,12:507.
- ↑ 2.0 2.1 Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer research. 1999,59(23):5975-9.
Basic Information
| Transcript ID |
ENST00000412654.1 |
| Source |
Gencode19 |
| Same with |
lnc-FOXB2-1:1, PCA3, DD3, PCAT3 |
| Classification |
intergenic |
| Length |
3922 nt |
| Genomic location |
chr9+:79379352..79402485 |
| Exon number |
4 |
| Exons |
79379352..79379471,79397584..79397748,79398621..79398803,79399032..79402485 |
| Genome context |
|
| Sequence |
000001 ACAGAAGAAA TAGCAAGTGC CGAGAAGCTG GCATCAGAAA AACAGAGGGG AGATTTGTGT GGCTGCAGCC GAGGGAGACC 000080
000081 AGGAAGATCT GCATGGTGGG AAGGACCTGA TGATACAGAG GAATTACAAC ACATATACTT AGTGTTTCAA TGAACACCAA 000160 000161 GATAAATAAG TGAAGAGCTA GTCCGCTGTG AGTCTCCTCA GTGACACAGG GCTGGATCAC CATCGACGGC ACTTTCTGAG 000240 000241 TACTCAGTGC AGCAAAGAAA GACTACAGAC ATCTCAATGG CAGGGGTGAG AAATAAGAAA GGCTGCTGAC TTTACCATCT 000320 000321 GAGGCCACAC ATCTGCTGAA ATGGAGATAA TTAACATCAC TAGAAACAGC AAGATGACAA TATAATGTCT AAGTAGTGAC 000400 000401 ATGTTTTTGC ACATTTCCAG CCCCTTTAAA TATCCACACA CACAGGAAGC ACAAAAGGAA GCACAGAGAT CCCTGGGAGA 000480 000481 AATGCCCGGC CGCCATCTTG GGTCATCGAT GAGCCTCGCC CTGTGCCTGG TCCCGCTTGT GAGGGAAGGA CATTAGAAAA 000560 000561 TGAATTGATG TGTTCCTTAA AGGATGGGCA GGAAAACAGA TCCTGTTGTG GATATTTATT TGAACGGGAT TACAGATTTG 000640 000641 AAATGAAGTC ACAAAGTGAG CATTACCAAT GAGAGGAAAA CAGACGAGAA AATCTTGATG GCTTCACAAG ACATGCAACA 000720 000721 AACAAAATGG AATACTGTGA TGACATGAGG CAGCCAAGCT GGGGAGGAGA TAACCACGGG GCAGAGGGTC AGGATTCTGG 000800 000801 CCCTGCTGCC TAAACTGTGC GTTCATAACC AAATCATTTC ATATTTCTAA CCCTCAAAAC AAAGCTGTTG TAATATCTGA 000880 000881 TCTCTACGGT TCCTTCTGGG CCCAACATTC TCCATATATC CAGCCACACT CATTTTTAAT ATTTAGTTCC CAGATCTGTA 000960 000961 CTGTGACCTT TCTACACTGT AGAATAACAT TACTCATTTT GTTCAAAGAC CCTTCGTGTT GCTGCCTAAT ATGTAGCTGA 001040 001041 CTGTTTTTCC TAAGGAGTGT TCTGGCCCAG GGGATCTGTG AACAGGCTGG GAAGCATCTC AAGATCTTTC CAGGGTTATA 001120 001121 CTTACTAGCA CACAGCATGA TCATTACGGA GTGAATTATC TAATCAACAT CATCCTCAGT GTCTTTGCCC ATACTGAAAT 001200 001201 TCATTTCCCA CTTTTGTGCC CATTCTCAAG ACCTCAAAAT GTCATTCCAT TAATATCACA GGATTAACTT TTTTTTTTAA 001280 001281 CCTGGAAGAA TTCAATGTTA CATGCAGCTA TGGGAATTTA ATTACATATT TTGTTTTCCA GTGCAAAGAT GACTAAGTCC 001360 001361 TTTATCCCTC CCCTTTGTTT GATTTTTTTT CCAGTATAAA GTTAAAATGC TTAGCCTTGT ACTGAGGCTG TATACAGCCA 001440 001441 CAGCCTCTCC CCATCCCTCC AGCCTTATCT GTCATCACCA TCAACCCCTC CCATGCACCT AAACAAAATC TAACTTGTAA 001520 001521 TTCCTTGAAC ATGTCAGGCA TACATTATTC CTTCTGCCTG AGAAGCTCTT CCTTGTCTCT TAAATCTAGA ATGATGTAAA 001600 001601 GTTTTGAATA AGTTGACTAT CTTACTTCAT GCAAAGAAGG GACACATATG AGATTCATCA TCACATGAGA CAGCAAATAC 001680 001681 TAAAAGTGTA ATTTGATTAT AAGAGTTTAG ATAAATATAT GAAATGCAAG AGCCACAGAG GGAATGTTTA TGGGGCACGT 001760 001761 TTGTAAGCCT GGGATGTGAA GCAAAGGCAG GGAACCTCAT AGTATCTTAT ATAATATACT TCATTTCTCT ATCTCTATCA 001840 001841 CAATATCCAA CAAGCTTTTC ACAGAATTCA TGCAGTGCAA ATCCCCAAAG GTAACCTTTA TCCATTTCAT GGTGAGTGCG 001920 001921 CTTTAGAATT TTGGCAAATC ATACTGGTCA CTTATCTCAA CTTTGAGATG TGTTTGTCCT TGTAGTTAAT TGAAAGAAAT 002000 002001 AGGGCACTCT TGTGAGCCAC TTTAGGGTTC ACTCCTGGCA ATAAAGAATT TACAAAGAGC TACTCAGGAC CAGTTGTTAA 002080 002081 GAGCTCTGTG TGTGTGTGTG TGTGTGTGAG TGTACATGCC AAAGTGTGCC TCTCTCTCTT TGACCCATTA TTTCAGACTT 002160 002161 AAAAACAAGC ATGTTTTCAA ATGGCACTAT GAGCTGCCAA TGATGTATCA CCACCATATC TCATTATTCT CCAGTAAATG 002240 002241 TGATAATAAT GTCATCTGTT AACATAAAAA AAGTTTGACT TCACAAAAGC AGCTGGAAAT GGACAACCAC AATATGCATA 002320 002321 AATCTAACTC CTACCATCAG CTACACACTG CTTGACATAT ATTGTTAGAA GCACCTCGCA TTTGTGGGTT CTCTTAAGCA 002400 002401 AAATACTTGC ATTAGGTCTC AGCTGGGGCT GTGCATCAGG CGGTTTGAGA AATATTCAAT TCTCAGCAGA AGCCAGAATT 002480 002481 TGAATTCCCT CATCTTTTAG GAATCATTTA CCAGGTTTGG AGAGGATTCA GACAGCTCAG GTGCTTTCAC TAATGTCTCT 002560 002561 GAACTTCTGT CCCTCTTTGT GTTCATGGAT AGTCCAATAA ATAATGTTAT CTTTGAACTG ATGCTCATAG GAGAGAATAT 002640 002641 AAGAACTCTG AGTGATATCA ACATTAGGGA TTCAAAGAAA TATTAGATTT AAGCTCACAC TGGTCAAAAG GAACCAAGAT 002720 002721 ACAAAGAACT CTGAGCTGTC ATCGTCCCCA TCTCTGTGAG CCACAACCAA CAGCAGGACC CAACGCATGT CTGAGATCCT 002800 002801 TAAATCAAGG AAACCAGTGT CATGAGTTGA ATTCTCCTAT TATGGATGCT AGCTTCTGGC CATCTCTGGC TCTCCTCTTG 002880 002881 ACACATATTA GCTTCTAGCC TTTGCTTCCA CGACTTTTAT CTTTTCTCCA ACACATCGCT TACCAATCCT CTCTCTGCTC 002960 002961 TGTTGCTTTG GACTTCCCCA CAAGAATTTC AACGACTCTC AAGTCTTTTC TTCCATCCCC ACCACTAACC TGAATGCCTA 003040 003041 GACCCTTATT TTTATTAATT TCCAATAGAT GCTGCCTATG GGCTATATTG CTTTAGATGA ACATTAGATA TTTAAAGCTC 003120 003121 AAGAGGTTCA AAATCCAACT CATTATCTTC TCTTTCTTTC ACCTCCCTGC TCCTCTCCCT ATATTACTGA TTGCACTGAA 003200 003201 CAGCATGGTC CCCAATGTAG CCATGCAAAT GAGAAACCCA GTGGCTCCTT GTGGTACATG CATGCAAGAC TGCTGAAGCC 003280 003281 AGAAGGATGA CTGATTACGC CTCATGGGTG GAGGGGACCA CTCCTGGGCC TTCGTGATTG TCAGGAGCAA GACCTGAGAT 003360 003361 GCTCCCTGCC TTCAGTGTCC TCTGCATCTC CCCTTTCTAA TGAAGATCCA TAGAATTTGC TACATTTGAG AATTCCAATT 003440 003441 AGGAACTCAC ATGTTTTATC TGCCCTATCA ATTTTTTAAA CTTGCTGAAA ATTAAGTTTT TTCAAAATCT GTCCTTGTAA 003520 003521 ATTACTTTTT CTTACAGTGT CTTGGCATAC TATATCAACT TTGATTCTTT GTTACAACTT TTCTTACTCT TTTATCACCA 003600 003601 AAGTGGCTTT TATTCTCTTT ATTATTATTA TTTTCTTTTA CTACTATATT ACGTTGTTAT TATTTTGTTC TCTATAGTAT 003680 003681 CAATTTATTT GATTTAGTTT CAATTTATTT TTATTGCTGA CTTTTAAAAT AAGTGATTCG GGGGGTGGGA GAACAGGGGA 003760 003761 GGGAGAGCAT TAGGACAAAT ACCTAATGCA TGTGGGACTT AAAACCTAGA TGATGGGTTG ATAGGTGCAG CAAACCACTA 003840 003841 TGGCACACGT ATACCTGTGT AACAAACCTA CACATTCTGC ACATGTATCC CAGAACGTAA AGTAAAATTT AAAAAAAAGT 003920 003921 GA |
